Hydroxyurea dose optimisation for children with sickle cell anaemia in sub-Saharan Africa (REACH): extended follow-up of a multicentre, open-label, phase 1/2 trial.Aygun B, Lane A, Smart LR, Santos B, Tshilolo L, Williams TN, Olupot-Olupot P, Stuber SE, Tomlinson G, Latham T, Ware RE
Lancet Haematol, (2024). S2352-3026:00078-4

Hydroxyurea dose optimisation for children with sickle cell anaemia in sub-Saharan Africa (REACH): extended follow-up of a multicentre, open-label, phase 1/2 trial.Aygun B, Lane A, Smart LR, Santos B, Tshilolo L, Williams TN, Olupot-Olupot P, Stuber SE, Tomlinson G, Latham T, Ware RE
Lancet Haematol, (2024). 11:e425-e435

Filling the data gaps on sickle cell anaemia in sub-Saharan Africa.Williams TN
Lancet Haematol, (2022). 9:e172-e173

Human candidate gene polymorphisms and risk of severe malaria in children in Kilifi, Kenya: a case-control association study.Ndila CM, Uyoga S, Macharia AW, Nyutu G, Peshu N, Ojal J, Shebe M, Awuondo KO, Mturi N, Tsofa B, Sepulveda N, Clark TG, Band G, Clarke G, Rowlands K, Hubbart C, Jeffreys A, Kariuki S, Marsh K, Mackinnon M, Maitland K, Kwiatkowski DP, Rockett KA, Williams TN, Malaria GENConsortium
Lancet Haematol, (2018). 5:e333-e345

Red blood cell variants and malaria: a long story not yet over.Williams TN
Lancet Haematol, (2015). 2:e130-1

Glucose-6-phosphate dehydrogenase deficiency and the risk of malaria and other diseases in children in Kenya: a case-control and a cohort study.Uyoga S, Ndila CM, Macharia AW, Nyutu G, Shah S, Peshu N, Clarke GM, Kwiatkowski DP, Rockett KA, Williams TN, Malaria GENConsortium
Lancet Haematol, (2015). 2:e437-44

Managing the burden of sickle-cell disease in Africa.Piel FB, Rees DC, Williams TN
Lancet Haematol, (2014). 1:e11-2